Latigo Biotherapeutics, Inc. (LTGO) stock
LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.76+1.16 (+9.21%)
Close on Nov 17, 2026Market cap $912.28MP/E –Yield 0.00%
Latigo Biotherapeutics operating margin
Operating margin is operating income as a percentage of revenue.
No operating margin figures for Latigo Biotherapeutics
Latigo Biotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?